ProKidney Corp.
Neil Robbins is an experienced Process Development Scientist at ProKidney Corp. since December 2015, specializing in cell-based therapeutic renal products. Previously, Robbins held the position of Scientist at RegenMedTX, where protocols and procedures for renal therapies were developed, and served as Director of Development at PBS Biotech, Inc., overseeing laboratory expansion for MSC production. At Tengion, Robbins focused on designing closed systems and bioreactors for transplantable tissues, contributing to clinical trials for products like Neo Kidney Augment and Neo Urinary Conduit. An extensive background as a Scientist at Becton Dickinson included work on life science products and patents. Early military service as a Sergeant in the Air Force National Guard involved aircraft armament and chemical warfare survival training. Robbins earned a degree from the University of Massachusetts Amherst between 1985 and 1989.
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.